Showing results (571-580 of 590) with videos related to

Sort By:
Pageof 59
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapseE L Sievers, R A Larson, E A Stadtmauer, et al.
Blood|October 29, 2005
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remissionJohn M Pagel, Frederick R Appelbaum, Janet F Eary, et al.
Genes, Chromosomes & Cancer|July 15, 2005
Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemiaDavid A Sweetser, Andrew J Peniket, Christina Haaland, et al.
The Journal of Pediatrics|June 1, 1997
Long-term survivors of pediatric heart transplantation: a multicenter report of sixty-eight children who have survived longer than five yearsG Sigfússon, F J Fricker, D Bernstein, et al.
Cancer|August 24, 2005
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrenceRichard A Larson, Eric L Sievers, Edward A Stadtmauer, et al.
Elife|February 26, 2015
Angiopoietin-like proteins stimulate HSPC development through interaction with notch receptor signalingMichelle I Lin, Emily N Price, Sonja Boatman, et al.
Molecular Therapy. Methods & Clinical Development|September 24, 2025
Directed evolution of liver-detargeted AAV vectors for systemic gene delivery to skeletal muscle and heartElad Firnberg, Sigmund K S Tejada, Samantha A Yost, et al.
Blood|October 26, 2000
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomasO W Press, J F Eary, T Gooley, et al.
Blood|June 18, 2013
SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AMLMay S Kung Sutherland, Roland B Walter, Scott C Jeffrey, et al.
Blood|January 9, 2010
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AMLJessica A Pollard, Todd A Alonzo, Robert B Gerbing, et al.
Pageof 59